drugset
drugset / Trial / NCT04296240

Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer

NCT04296240 ↗

Phase 2 Unknown 119 enrolled Peking University Cancer Hospital & Institute
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to test the Safety and efficacy of induction and individualized neoadjuvant chemotherapy based on oxaliplatin combined with fluorouracil for MRF-negative, moderate-risk and initially resectable middle and low rectal cancer.

Timeline

Start
2019-03-01
Primary completion
2021-04
Completion
2024-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1250 mg/m2 —
Subject Oxaliplatin Small molecule 130 mg/m2 —

Indications

rectal cancer